Halozyme (NASDAQ:HALO) has raised its financial guidance estimates for 2025 based on expected strong sales of products ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today provided a financial update, reiterating full ...

Analyst Jason Butler of JMP Securities reiterated a Buy rating on Halozyme (HALO – Research Report), retaining the price target of $73.00.Stay ...

EST Halozyme (HALO) announces new $250M accelerated share repurchase plan Stay Ahead of the Market:Discover outperforming stocks and ...

Industry executive with more than 25 years of finance and strategic leadership experienceBOSTON and SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage ...

SpringWorks Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating ...

This video shows the plane plunging into the sea after take off, a manoeuvre aviation investigators will probe.

Halozyme Therapeutics stock is trading -17.97% below its average target price of $64.12 after marking a 2.8% during today's morning session. Analysts are giving the Mid-Cap Biotechnology company an ...

The traditional carnival-like "Ragoutsaria" celebration is wrapping up today, January 8, in the city of Kastoria, northern Greece, seeing locals donning colorful costumes and dancing in the streets of ...